May 15 (SeeNews) - Croatian pharmaceuticals producer Jadran Galenski Laboratorij (JGL) said it has signed a strategic partnership deal with Poland's Polpharma, considering potential collaboration on the Russian market.
The deal also envisages cross-licensing of prescription and non-prescription drugs as well as transfer of manufacturing of preservative-free ophthalmic products, JGL said in a statement last week after the signing of the agreement.
In addition, part of Polpharma’s portfolio will be manufactured in JGL’s plants in Rijeka for sale on the Croatian and other European markets, the statement reads.
"This collaboration demonstrates JGL’s strength and competitiveness on the global market and competence of our employees, especially in the field of ophthalmology which is our core therapeutic area," JGL CEO, Mislav Vucic, said.
The two companies have already started joint work on the agreed projects, with the first results of the cooperation expected in 2019.
JGL is already present in Russia, which is among its largest markets along with Croatia, Ukraine and Kazakhstan.
Founded in 1991, JGL is one of the largest drug makers in Croatia, specialising in the production of sterile nose, eye and ear drop solutions.